Brainsway Ltd

Research Brainsway Ltd (BWAY) on Bullrun: valuation model: 36.8% overvalued, market cap USD 607.30M, P/E 67.8. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBWAY
• ExchangeNASDAQ
• CountryIsrael
• SectorHealthcare
• IndustryMedical Devices
• CurrencyUSD
• Valuation signal36.8% overvalued
• Market capUSD 607.30M
• P/E67.8
• Financial periodQ1 2026
• RevenueUSD 56.22M
• Net incomeUSD 8.76M
• Free cash flowUSD 402.00K
• Gross margin75.5%

Valuation Snapshot

Bullrun's latest valuation model marks Brainsway Ltd as 36.8% overvalued; latest market cap is USD 607.30M; P/E is 67.8.

About Brainsway Ltd

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally.

Frequently asked questions

Is Brainsway Ltd overvalued or undervalued?

Bullrun's valuation model currently marks Brainsway Ltd as 36.8% overvalued.

What is Brainsway Ltd's market cap?

Brainsway Ltd's market capitalization is USD 607.30M.

What is Brainsway Ltd's P/E ratio?

Brainsway Ltd's price-to-earnings (P/E) ratio is 67.8.

What does Brainsway Ltd do?

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally.